Low dose erythropoietin‐beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa‐2b

Tseng, Kuo‐Chih; Chen, Li-Hsuan; Chen, Chi-Yi; Chang, Ting‐Tsung; Chou, An-Liang; Wu, I‐Chin; Cheng, Pin-Nan

doi:10.1111/j.1872-034x.2009.00489.x

Cited by 11 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current data showed that HCV genotype 1 patients who failed a prior standard of care had a lower chance of achieving SVR [90][91][92], giving new antiviral therapies more important role for patients. In conclusion, most of the new drugs described above need the combination of peg-IFN and RBV at the same time to allow them to work in an anti-HCV manner.…”

Section: Vitamin Dmentioning

confidence: 86%

New antiviral therapies for chronic hepatitis C

2010

View full text Add to dashboard Cite

Chronic hepatitis C is an important health issue worldwide. The current standard therapy is based on a combination of pegylated-interferon (pegIFN) and ribavirin (RBV), but this treatment leads to only ~50% sustained virological response (SVR) in patients with HCV genotype 1 and high viral loads, who were mostly null-responders or relapsers. Among HCV genotypes other than HCV genotype 1, especially HCV genotype 4 patients show only 40-70% SVR by this treatment. Although new drugs also depend on the combination of pegIFN and RBV, it appears that these drugs improve not only rapid virological response (RVR) but also early virological response, leading to SVR in these patients. In the near future, we predict higher SVR rates in chronic hepatitis C patients treated with these new drugs.

show abstract

Section: Vitamin Dmentioning

confidence: 86%

New antiviral therapies for chronic hepatitis C

2010

View full text Add to dashboard Cite

show abstract

“…Erythropoietic growth factor, erythropoietin, is widely used in the USA and some Western countries to increase hemoglobin level, maintain the doses of RBV and improve treatment compliance. [11][12][13][14][15][16][17][18][19][20][21] However, the adjuvant use of erythropoietin in the setting of anti-HCV therapy has not been approved in Japan. 22 In addition, the impact of erythropoietin administration on SVR remains unclear.…”

Section: H Epatitis C Virus (Hcv) Infection Remains Anmentioning

confidence: 99%

Adjuvant epoetin‐β with peginterferon‐α and ribavirin in Japanese ribavirin‐intolerant relapsed patients with chronic hepatitis C genotype 2

Enomoto

Morikawa

Murakami

et al. 2013

Hepatology Research

View full text Add to dashboard Cite

Erythropoietin is widely used in the USA and some other Western countries to maintain doses of ribavirin during peginterferon/ribavirin-based treatment for chronic hepatitis C virus (HCV) infection. However, the impact of erythropoietin on sustained virological response (SVR) is unclear. Here, we report the cases of three Japanese ribavirin-intolerant relapsed patients with HCV genotype 2 who achieved SVR from retreatment by adding erythropoietin. Three women aged 50, 64 and 68 years with chronic HCV genotype 2 received retreatment with peginterferon-α and ribavirin. During their prior therapy, HCV RNA became negative according to real-time polymerase chain reaction at weeks 4-8 in all three patients; however, the total dose of ribavirin was 18.1-30.6% lower than the planned dose, and HCV RNA relapsed post-treatment. At present, epoetin-β 24 000 IU was introduced at weeks 2 or 3 of dual-combination therapy, resulting in a less than 4.2% reduction in the total dose of ribavirin. HCV RNA became negative at weeks 4-8, and all patients achieved SVR. Until the next-generation antiviral treatments for HCV genotype 2 become available, the addition of erythropoietin to dual therapy can be a treatment of choice for ribavirin-intolerant relapsed patients.

show abstract

“…To overcome this obstacle, several groups reported employment of human recombinant erythropoietin (EPO) administration to alleviate anemia and thereby complete the therapy without RBV reduction in patients under IFN/RBV or PEG IFN/RBV combination therapy. [3][4][5][6][7][8] Most of the reports describe the successful role of EPO as an alternative to RBV dose reduction, and meta-analysis demonstrates that EPO administration can considerably enhance SVR with no adverse event due to EPO. 9 In triple therapy, anemia develops more frequently than in PEG IFN/RBV combination therapy, consequently resulting in poor adherence to RBV.…”

Section: Introductionmentioning

confidence: 99%

Administration of low‐dose epoetin‐alpha facilitates adherence to ribavirin in triple therapy with pegylated interferon‐alpha‐2b and telaprevir

Ishida

Sakane

Toyama

et al. 2014

Hepatology Research

View full text Add to dashboard Cite

show abstract

Low dose erythropoietin‐beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa‐2b

Abstract: Low-dose EPO-beta can maintain RBV dose and increase Hb levels in anemic chronic HCV patients receiving combination therapy.

Cited by 11 publications

References 27 publications

New antiviral therapies for chronic hepatitis C

New antiviral therapies for chronic hepatitis C

Adjuvant epoetin‐β with peginterferon‐α and ribavirin in Japanese ribavirin‐intolerant relapsed patients with chronic hepatitis C genotype 2

Administration of low‐dose epoetin‐alpha facilitates adherence to ribavirin in triple therapy with pegylated interferon‐alpha‐2b and telaprevir

Contact Info

Product

Resources

About